Genetics

Global Genes Awards 2022 Financial Advocacy in Rare (FAIR) Patient Impact Grants to Fund Impactful Programs in Rare Disease Communities

Retrieved on: 
Wednesday, June 22, 2022
Research, Genetics, Philanthropy, Other Health, Other Education, General Health, Health, Other Philanthropy, Science, Education, Global Genes, FSR, Degenerative disease, All India Institutes of Medical Sciences, Lists of diseases, CEO, FAIR, Knowledge, Anti-transglutaminase antibodies, Research, Episcopal conference, PWS, Disease, Program, Policy, Corporation, Caregiver, SCD, Family, Micro Tech Global Foundation, Patient, Employment, Medicine, Diagnosis, Awareness, Conference, Love, Horizon Therapeutics, Face, Organization, Pharmaceutical industry, Health insurance, Pfizer

Global Genes , a leading rare disease patient advocacy organization, today announced the recipients of their annual Financial Advocacy in RARE Patient Impact (FAIR) Grant .

Key Points: 
  • Global Genes , a leading rare disease patient advocacy organization, today announced the recipients of their annual Financial Advocacy in RARE Patient Impact (FAIR) Grant .
  • Families with rare disease often face significantly higher hurdles both from an overall financial perspective and in accessing specialized medical services and treatments.
  • Through our RARE Patient Impact Grants program, we are pleased to support patient advocacy organizations that are helping their communities better tackle issues that impact financial well-being and access to needed care.
  • If you or someone you love has a rare disease or are searching for a diagnosis, contact Global Genes at 949-248-RARE or visit our Resource Hub .

Cerebras Systems Sets Record for Largest AI Models Ever Trained on a Single Device

Retrieved on: 
Wednesday, June 22, 2022
Semiconductor, Technology, Software, Networks, Artificial Intelligence, Hardware, System, Solution, GlaxoSmithKline, Industry, Leibniz Supercomputing Centre, Argonne National Laboratory, AstraZeneca, GSK, Memory, Weight, CS-2, Natural language processing, Government, Graphics processing unit, CEO, Edinburgh Parallel Computing Centre, Pittsburgh Supercomputing Center, Research, Entrepreneurship, Genetics, HPC, Engineering, National Center for Computational Sciences, Ecosystem, Lawrence Livermore National Laboratory, EPCC, Artificial intelligence, National Center for Supercomputing Applications, SVP, Deep learning, Rest, Machine learning, GPU, NLP, National Energy Technology Laboratory, AI, Video game console, Online shopping, Medical device, Cerebra (British charity)

By enabling a single CS-2 to train these models, Cerebras reduces the system engineering time necessary to run large natural language processing (NLP) models from months to minutes.

Key Points: 
  • By enabling a single CS-2 to train these models, Cerebras reduces the system engineering time necessary to run large natural language processing (NLP) models from months to minutes.
  • The Cerebras CS-2 is a critical component that allows GSK to train language models using biological datasets at a scale and size previously unattainable.
  • These foundational models form the basis of many of our AI systems and play a vital role in the discovery of transformational medicines.
  • Cerebras ability to bring large language models to the masses with cost-efficient, easy access opens up an exciting new era in AI.

Labster Showcases Comprehensive High School Science EdTech Solution Package at ISTELive Expo in New Orleans

Retrieved on: 
Wednesday, June 22, 2022
Apps, Applications, Technology, Other Technology, Software, Internet, Primary, Secondary, Consumer Electronics, Science, Education, Other Science, ESSA, Education, Biochemistry, Learning, Android, Science, Chrome OS, Genetics, Chrome, Workload, Teacher, School, Biology, Chemistry, Google Classroom, Biotechnology, Student, Research, Technology, Educational technology, Curriculum, Tablet, Program, IOS, International Society, Chromebook, University, Jacques-André Istel, IPad, Physics, Computer, STEM, Ernest, Video game, Tutoring, Medicine

The company will demonstrate how the immersive virtual 3D Labster simulations stream seamlessly across devices powered by 12th Gen Intel Core mobile processors.

Key Points: 
  • The company will demonstrate how the immersive virtual 3D Labster simulations stream seamlessly across devices powered by 12th Gen Intel Core mobile processors.
  • And with the new integrations were rolling out at ISTELive, high school teachers will find it even easier to weave Labster into their existing curriculum and systems.
  • For a full decade , Labster EdTech has provided educators with the ability to digitally explore and enhance their science offerings.
  • ISTELive attendees who visit the Labster booth can also qualify for a special limited-time offer of simulations designed specifically for high school environments.

Zoetis Completes Acquisition of Basepaws, an Innovative Leader in Petcare Genetics, to Strengthen its Portfolio of Precision Animal Health Solutions

Retrieved on: 
Wednesday, June 22, 2022
Genetics, Health, Veterinary, COVID-19, Animal, Risk, Veterinarian, Annual report, PETS, Genetics, Vaccine, Forward-looking statement, Livestock, Disease, Farmer, Health, CA, Acquisition, Inc., Coronavirus, Genetic testing, NYSE, Cat, Pharmaceutical industry

The addition of Basepaws will enhance our portfolio in the precision animal health space and inform our future pipeline of petcare innovations.

Key Points: 
  • The addition of Basepaws will enhance our portfolio in the precision animal health space and inform our future pipeline of petcare innovations.
  • Basepaws is a petcare genetics company that builds early detection health risk tests based on genetic and microbiome data.
  • Basepaws is committed to companion animal health research, and it has the worlds first at-home genetic testing platform for cats.
  • As the worlds leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals.

OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients

Retrieved on: 
Wednesday, June 22, 2022
Gold, Culture, Karolinska University Hospital, Immunodeficiency, Genetics, Bacterial pneumonia, PPV, Hospital, Pneumocystis pneumonia, Drug Quality and Security Act, PCR, GLOBE, Solution, KUH, Infection, Observation, Technology, Nadine Opgen-Rhein, Pneumonia, Private Securities Litigation Reform Act, Comparison, Nasdaq, Urinary tract infection, FDA, COVID-19, Evaluation, Adoption, Securities Act of 1933, Karolinska Institute, NGS, PCP, Bureau of Oceans and International Environmental and Scientific Affairs, Adult, HPN, Patient, Pneumocystis jirovecii, Diagnosis, Collection, Securities Exchange Act of 1934, LRT, Precision medicine, U.S. Securities and Exchange Commission, NPV, Goal, Vaccine, Pharmaceutical industry, MD

The publication highlights the ability of the Unyvero Hospitalized Pneumonia panel in detecting potential pneumonia pathogens earlier than culture or very early during an infection.

Key Points: 
  • The publication highlights the ability of the Unyvero Hospitalized Pneumonia panel in detecting potential pneumonia pathogens earlier than culture or very early during an infection.
  • This enables reliable and rapid diagnosis of pathogens of concern in these patients directly from native lower respiratory tract samples, and provides identification of bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.
  • In their new publication titled Evaluation of a pneumonia multiplex PCR panel for detection of bacterial respiratory tract pathogens from serial specimens collected from hospitalized COVID-19 patients 2, the investigators conducted a follow-up study aimed to examine the concordant and discrepant results comparing the Unyvero HPN and culture results for detection of microorganisms from serial specimens collected from the same patient.
  • This press release includes statements regarding the publication of results of a recent study of the Unyvero Hospitalized Pneumonia panel.

Ligandal Partners With Nanotronics to Solidify Optimization and Quality in Personalized Genomic Medicine Delivery Systems

Retrieved on: 
Wednesday, June 22, 2022
Engineering, Chemicals, Plastics, Defense, Technology, Manufacturing, Other Health, Pharmaceutical, Semiconductor, Security, Satellite, Photography, Nanotechnology, Genetics, Science, Health, Other Technology, Other Science, Other Manufacturing, Research, Networks, Other Defense, Hardware, Laboratory, Economic development, Cancer, National Institutes of Health, Therapy, COVID-19, Nanomedicine, Safety, Collaboration, Computational biology, Brooklyn Navy Yard, Degenerative disease, Intelligence, Infection, Regenerative medicine, Electronics, CEO, EVP, Bone marrow, Peptide, Growth, Ecosystem, Gene editing, Inc., National Institute, Public health, Partnership, Lists of diseases, Software, Medicine, NIAID, Multimedia, National Institute of Allergy and Infectious Diseases, COVID, Hematology, Machine learning, AI, National, Immunotherapy, NIH, 3D printing, Vaccine, Nanotronics Imaging, GDNF family of ligands

This will allow the delivery of gene therapies exactly where they need to go, with precision and without the issues seen with viral delivery systems, he continued.

Key Points: 
  • This will allow the delivery of gene therapies exactly where they need to go, with precision and without the issues seen with viral delivery systems, he continued.
  • Ligandal is developing next-generation, precision genetic nanomedicine and delivery technologies for gene editing, gene therapy, regenerative medicine, and pandemic defense biotechnology applications.
  • The company uses computational biology, machine learning, and AI with a novel platform for cell-specific and tissue-specific delivery and next-generation nanomaterials.
  • A leading developer of automated optical inspection tools for the semiconductor industry, Nanotronics uses hardware and software to provide industrial-scale, high-throughput, super imaging systems.

Nucleix Expands EU Label Indication of Bladder EpiCheck® to Include the Detection of Primary Bladder Cancer and Detection of Primary and Recurrent Upper Tract Urinary Cancer

Retrieved on: 
Wednesday, June 22, 2022
Biotechnology, Medical Devices, Health, Genetics, Oncology, Population, Union, Disease, Lung, Neoplasm, Malignancy, PCR, Bladder cancer, Life, Liquid biopsy, Technology, Cystoscopy, List of American Medical Association journals, DNA, Urinary bladder, Pathology, Squamous cell carcinoma, Ureter, Kidney, Triage, Recurrence, Medical Affairs Bureau, International Agency for Research on Cancer, NGS, Systematic review, Upper Tract, West Virginia, Organic, Erratum, Patient, IARC, Diagnosis, Blood, DNA methylation, The Journal of Urology, JAMA, Jurgis Matulaitis-Matulevičius, Research, Company, EMEA, UTUC, NPV, Sale, Medical imaging, Medical device, MD, Hematuria, Cancer, EU, Urine, Urology

With this expanded label indication and high specificity of Bladder EpiCheck in this population, were able to offer a cost-effective, non-invasive approach to triage hematuria patients and help identify bladder cancer early.

Key Points: 
  • With this expanded label indication and high specificity of Bladder EpiCheck in this population, were able to offer a cost-effective, non-invasive approach to triage hematuria patients and help identify bladder cancer early.
  • Bladder EpiCheck provides patients and clinicians with a simple, objective urine test to detect primary and recurrent bladder and upper urinary tract cancers.
  • Bladder EpiCheck is intended for use as a non-invasive method for detection of urinary tract cancers in conjunction with standard methods.
  • The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck testing kit, marketed in Europe for the detection of primary and recurrent bladder cancer and Upper Tract Urinary Cancer.

Nutcracker Therapeutics Bolsters Leadership with Chief Operating Officer and Other Key Hires, Reveals Oncology Pipeline

Retrieved on: 
Wednesday, June 22, 2022
Software, Biotechnology, Networks, Pharmaceutical, Oncology, Health, Technology, Genetics, Industry, RNA, Senior, University, Therapy, AstraZeneca, MBA, Vaccine, Technology, Irell & Manella Graduate School of Biological Sciences, CBO, Corporation, Business, Manufacturing, Wharton School of the University of Pennsylvania, Leadership, Growth, General counsel, Policy, General manager, Acquisition, Gilead Sciences, T-cell lymphoma, Patient, Chemical engineering, RNA transfection, Pharmaceutical industry, Management, Nutcracker, Immunomedics

Stubenrauch will help strengthen and expand Nutcracker Therapeutics operations, while also overseeing therapeutic manufacturing, quality, and supply management.

Key Points: 
  • Stubenrauch will help strengthen and expand Nutcracker Therapeutics operations, while also overseeing therapeutic manufacturing, quality, and supply management.
  • John brings invaluable leadership and industry experience to Nutcracker Therapeutics as the company continues taking decisive steps toward realizing the therapeutic potential of RNA for patients across multiple oncology indications, says Igor Khandros, Ph.D., co-founder and Chief Executive Officer of Nutcracker Therapeutics.
  • Nutcracker Therapeutics has further expanded its senior leadership with Geoff Nosrati, Ph.D., as Chief Business Officer (CBO), and Ian Wiener, J.D., as Executive Vice President and General Counsel.
  • These leadership additions follow Nutcracker Therapeutics recent $167 million in Series C financing , led by ARCH Venture Partners.

Phibro Animal Health Corporation and Rejuvenate Bio Announce Agreement to Develop Gene Therapy for Mitral Valve Disease in Canines

Retrieved on: 
Wednesday, June 22, 2022
Veterinary, Research, Genetics, Cardiology, Biotechnology, Other Health, Health, Other Science, Science, Dog, Solution, Heart, Animal, Wyss Institute for Biologically Inspired Engineering, Veterinarian, Genetics, Harvard Medical School, Ageing, CEO, PAHC, Wyss Institute, Research, Human, Disease, George Church, Heart failure, Farmer, Health, Harvard University, Nasdaq, Phibro, Death, Incidence, MVD, Adrenal insufficiency, Mitral valve, Degenerative disease, Blood, Pharmaceutical industry

Phibro Animal Health Corporation (Nasdaq:PAHC) and Rejuvenate Bio, Inc. today announced a collaboration for the development and commercialization of a gene therapy for Mitral Valve Disease (MVD) in canines (dogs).

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq:PAHC) and Rejuvenate Bio, Inc. today announced a collaboration for the development and commercialization of a gene therapy for Mitral Valve Disease (MVD) in canines (dogs).
  • Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company.
  • Rejuvenate Bio is a spinout from the Wyss Institute at Harvard focused on reversing aging and eliminating age-related disease.
  • Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to humans and canines suffering from age-related conditions.

Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022

Retrieved on: 
Wednesday, June 22, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Poster, Disease management, Recurrence, Skin cancer, Dermatology, American Joint Committee on Cancer, Risk, Health, List of life sciences, Nasdaq, Patient, Conference, CM, Melanoma, Neoplasm, Medical imaging

Data on each of Castles skin cancer tests, as outlined below, was shared during the recent Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2022.

Key Points: 
  • Data on each of Castles skin cancer tests, as outlined below, was shared during the recent Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2022.
  • A high-risk Class 2B test result was a significant predictor of disease recurrence (HR=4.49, p=0.001), similar to a positive sentinel lymph node (SLN) (HR=4.46, p
  • As a positive SLN is evidence that a patients melanoma has spread, these patients are candidates for advanced imaging and potentially, adjuvant therapies.
  • Castles DecisionDx-SCC test was designed to address this unmet medical need for patients with SCC and one or more high-risk factors.